Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma × eribulin × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 21 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 4 Sarcoma 2 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Meningeal Neoplasms 1 Meningeal Carcinomatosis 1 HR+HER2- Breast Cancer 1 HER2-low Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Carcinoma 1 Brain Neoplasms 1

Interventions

Carboplatin 15 Cisplatin 12 Paclitaxel 11 Pemetrexed 10 pembrolizumab 8 Gemcitabine 7 Docetaxel 6 durvalumab 4 Sorafenib 4 130-nm albumin-bound paclitaxel 4 osimertinib 3 cabozantinib 3 Taxes 3 Radiotherapy 3 Mitomycin 3 Magnetic Resonance Spectroscopy 3 Cetuximab 3 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3 trifluridine tipiracil drug combination 2 regorafenib 2 padeliporfin 2 olaparib 2 atezolizumab 2 Sunitinib 2 Specimen Handling 2 Radiotherapy, Intensity-Modulated 2 Radiation 2 Nivolumab 2 Irinotecan 2 Everolimus 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02915744 2023-04-14

ATTAIN

Nektar Therapeutics

Phase 3 Completed

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡